Related Experiment Video
Updated: Mar 13, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.7K
DOACs - advances and limitations in real world
1Department of Haematology, Singapore General Hospital, 20, College Road, Academia Level 3, Singapore, 169856 Singapore.
Thrombosis Journal
|October 22, 2016
Summary
Direct oral anticoagulants (DOACs) offer significant advancements in antithrombotic therapy. While effective, further research and education are needed for broader patient populations and safe clinical management.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Direct oral anticoagulants (DOACs), formerly novel oral anticoagulants (NOACs), represent a significant advancement in antithrombotic therapy.
- Clinical trials demonstrate favorable results for DOACs in preventing and treating arterial and venous thrombotic diseases.
Approach:
- DOACs are increasingly used in routine clinical practice, with real-world data supporting trial findings.
- Ongoing development of specific antidotes and reliable coagulation assays aims to enhance confidence and safety in DOAC use.
Key Points:
- DOACs like dabigatran, rivaroxaban, apixaban, and edoxaban are established treatments.
- Limitations include lack of data in specific patient groups (pediatric, atrial fibrillation with valvular heart disease, antiphospholipid syndrome, cancer-associated thrombosis) and potential issues with affordability and access.
- Clinician education on DOAC management, including drug selection and bleeding complication handling, is crucial for patient safety.
Conclusions:
- DOACs are a major addition to antithrombotic options, with expected increased usage.
- Addressing data gaps in specific populations and ensuring accessibility are key for wider adoption.
- Comprehensive clinician education is vital to optimize DOAC therapy and mitigate risks.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:29Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
418
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
418
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
614
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
614